Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 29, 2026

Why Power Integrations (POWI) Is Up 6.6% After Launching 440 W TOPSwitchGaN Flyback ICs

View original at finance.yahoo.com
Why Power Integrations (POWI) Is Up 6.6% After Launching 440 W TOPSwitchGaN Flyback ICs In March 2026, Power Integrations introduced its TOPSwitchGaN flyback IC family using PowiGaN technology, extending flyback converter power capability to 440 W while improving efficiency and reducing system complexity and cost acros…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rising Asian competition and tariff uncertainty could pose risks to Power Integrations despite promising GaN wins

    60% confidence
  • This TOPSwitchGaN launch might eventually push the GaN and electrification thesis even further, or expose how much depends on the outcome of intensifying Asian competition and trade friction

    60% confidence
  • The most optimistic analysts were already assuming revenue could reach about US$658.6 million and earnings US$127.6 million by 2028

    60% confidence
  • The new TOPSwitchGaN flyback family strengthens the investment case by lifting flyback power to 440 W and simplifying designs, but does little to reduce near term exposure to tariffs and housing linked appliance softness

    60% confidence
  • Together with TOPSwitchGaN, the InnoSwitch3 AQ platform underscores how GaN based designs could shift the mix toward higher power, higher value applications in EV and industrial segments

    60% confidence
  • TOPSwitchGaN devices are pin-to-pin compatible with existing TinySwitch-5 ICs, potentially allowing designers to scale designs from 10 W to 440 W using a common methodology

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com